28 results
8-K
DRRX
Durect Corp
3 Feb 21
Results of Operations and Financial Condition
9:39pm
, COVID-19, has and will adversely impact our business.
The global COVID-19 pandemic has disrupted our operations and delayed our clinical trials … . In particular, the COVID-19 pandemic has delayed initiation of our AHFIRM Phase 2b clinical trial to evaluate the safety and efficacy of DUR-928
8-K
EX-99.1
DRRX
Durect Corp
11 May 20
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs
4:15pm
. “The first quarter was largely about adjusting to the challenges posed by the COVID-19 pandemic and planning our next clinical study of DUR-928 in alcoholic … acute respiratory syndrome coronavirus (SARS-COV-2). The rapid spread of the disease has resulted in a pandemic with more than 4 million confirmed cases
8-K
EX-99.1
ntxp5tb
2 Nov 20
DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs
12:00am
8-K
EX-99.1
o8w7y
3 Aug 20
DURECT Corporation Announces Second Quarter 2020 Financial Results and Update of Programs
4:21pm
8-K
EX-99.1
kd9zfwl
23 Sep 20
Other Events
9:01am
8-K
EX-99.1
pyrg7e9q9l4
1 Jul 20
Other Events
9:01am
8-K
EX-99.1
lhu3obcimc eho9wc
27 Aug 20
Other Events
8:45am
8-K
EX-99.1
9dk24b k6
26 May 20
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
9:00am
8-K
EX-99.1
u4qad
16 May 23
Regulation FD Disclosure
12:08pm